Vishram B. Rege

1.1k total citations
19 papers, 827 citations indexed

About

Vishram B. Rege is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Vishram B. Rege has authored 19 papers receiving a total of 827 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in Vishram B. Rege's work include Lung Cancer Treatments and Mutations (5 papers), Lung Cancer Research Studies (4 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). Vishram B. Rege is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Lung Cancer Research Studies (4 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). Vishram B. Rege collaborates with scholars based in United States, Switzerland and Canada. Vishram B. Rege's co-authors include Louis A. Leone, Maurice M. Albala, H. Choy, Caron Modeas, Michael Glantz, James E. Herndon, Gary M. Strauss, Noah C. Choi, Robert W. Carey and Douglas J. Mathisen and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Vishram B. Rege

19 papers receiving 753 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vishram B. Rege United States 14 484 449 105 98 77 19 827
Yoshio Gunji Japan 17 405 0.8× 375 0.8× 374 3.6× 254 2.6× 88 1.1× 46 1.2k
Anastasios Dimou United States 16 481 1.0× 311 0.7× 67 0.6× 201 2.1× 72 0.9× 67 800
Toshiro Yonei Japan 10 540 1.1× 503 1.1× 90 0.9× 85 0.9× 24 0.3× 28 855
Liangping Xia China 15 443 0.9× 158 0.4× 165 1.6× 105 1.1× 41 0.5× 45 691
Hiroshi Asoh Japan 23 593 1.2× 1.1k 2.4× 251 2.4× 109 1.1× 49 0.6× 50 1.5k
Gregory Gagnon United States 11 183 0.4× 218 0.5× 143 1.4× 135 1.4× 70 0.9× 17 561
Liming Sheng China 15 480 1.0× 273 0.6× 191 1.8× 165 1.7× 45 0.6× 44 784
P. Dohrmann Germany 14 185 0.4× 301 0.7× 193 1.8× 182 1.9× 56 0.7× 46 761
Mitsuhiro Takemoto Japan 17 315 0.7× 533 1.2× 190 1.8× 58 0.6× 114 1.5× 66 947
Alessandro Ribechini Italy 15 375 0.8× 502 1.1× 231 2.2× 289 2.9× 77 1.0× 38 1.1k

Countries citing papers authored by Vishram B. Rege

Since Specialization
Citations

This map shows the geographic impact of Vishram B. Rege's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vishram B. Rege with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vishram B. Rege more than expected).

Fields of papers citing papers by Vishram B. Rege

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vishram B. Rege. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vishram B. Rege. The network helps show where Vishram B. Rege may publish in the future.

Co-authorship network of co-authors of Vishram B. Rege

This figure shows the co-authorship network connecting the top 25 collaborators of Vishram B. Rege. A scholar is included among the top collaborators of Vishram B. Rege based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vishram B. Rege. Vishram B. Rege is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Akerley, Wallace, Michael Glantz, H. Choy, et al.. (1998). Phase I trial of weekly paclitaxel in advanced lung cancer.. Journal of Clinical Oncology. 16(1). 153–158. 102 indexed citations
3.
Akerley, Wallace, et al.. (1997). Weekly paclitaxel in patients with advanced lung cancer: preliminary data from a phase II trial.. PubMed. 24(4 Suppl 12). S12–10. 25 indexed citations
4.
Akerley, Wallace, et al.. (1997). 65 Weekly paclitaxel — Marked activity, diminished toxicity and platelet stimulating effect. Lung Cancer. 18. 19–20. 1 indexed citations
5.
Graziano, Stephen L., Frank H. Valone, James E. Herndon, et al.. (1996). A randomized Phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: A Cancer and Leukemia Group B study. Lung Cancer. 14(2-3). 315–329. 14 indexed citations
6.
Choy, H., Wallace Akerley, Howard Safran, et al.. (1994). Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer.. Journal of Clinical Oncology. 12(12). 2682–2686. 116 indexed citations
7.
Strauss, Gary M., James E. Herndon, Douglas J. Mathisen, et al.. (1992). Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study.. Journal of Clinical Oncology. 10(8). 1237–1244. 175 indexed citations
8.
9.
Maurer, L. Herbert, Thomas F. Pajak, Walter L. Eaton, et al.. (1985). Combined modality therapy with radiotherapy, chemotherapy, and immunotherapy in limited small-cell carcinoma of the lung: a Phase III cancer and Leukemia Group B Study.. Journal of Clinical Oncology. 3(7). 969–976. 39 indexed citations
10.
Rege, Vishram B., et al.. (1983). Hyperthermic adjuvant perfusion chemotherapy for stage I malignant melanoma of the extremity with literature review. Cancer. 52(11). 2033–2039. 32 indexed citations
11.
Ree, H. J., et al.. (1980). Malignant lymphoma of Waldeyer's ring following gastrointestinal lymphoma. Cancer. 46(7). 1528–1535. 47 indexed citations
12.
Hayes, Donald M., Thomas F. Pajak, Vishram B. Rege, et al.. (1979). Combination chemotherapy for non‐Hodgkin lymphomas: A ten year follow‐up study. Medical and Pediatric Oncology. 6(1). 23–38. 2 indexed citations
13.
Leone, Louis A., et al.. (1978). A combined treatment approach to management of hepatic metastases. Cancer. 42(3). 1087–1095. 33 indexed citations
14.
Leone, Louis A., et al.. (1977). A combined treatment approach to management of hepatic metastases. International Journal of Radiation Oncology*Biology*Physics. 2. 76–77. 1 indexed citations
15.
16.
Rege, Vishram B., Ramon Patel, & William A. Briggs. (1972). Leukocyte Antigens and Disease: II. Association of HL-A5 and Lymphomas. American Journal of Clinical Pathology. 58(1). 14–16. 8 indexed citations
17.
Leone, Louis A., Maurice M. Albala, & Vishram B. Rege. (1968). Treatment of carcinoma of the head and neck with intravenous methotrexate. Cancer. 21(5). 828–837. 70 indexed citations
18.
Stein, Martin H., et al.. (1966). Evaluation of spirometric methods used to assess abnormalities in airway resistance.. PubMed. 93(2). 257–63. 18 indexed citations
19.
Thomas, Duncan P., et al.. (1964). Mechanism of bronchoconstriction produced by thromboemboli in dogs. American Journal of Physiology-Legacy Content. 206(6). 1207–1212. 90 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yoshio Gunji Breakdown of academic impact, for papers by Anastasios Dimou Breakdown of academic impact, for papers by Toshiro Yonei Breakdown of academic impact, for papers by Liangping Xia Breakdown of academic impact, for papers by Hiroshi Asoh Breakdown of academic impact, for papers by Gregory Gagnon Breakdown of academic impact, for papers by Liming Sheng Breakdown of academic impact, for papers by P. Dohrmann Breakdown of academic impact, for papers by Mitsuhiro Takemoto Breakdown of academic impact, for papers by Alessandro Ribechini
Rankless by CCL
2026